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Objective 
MicroRNAs are important intracellular regulators of gene expression, but also circulate in the blood 
being protected by extracellular vesicles, proteins or high density lipoprotein (HDL). Here we 
evaluate the regulation and function of HDL-bound miRs in cardiovascular disease.  
 
Methods and Results 
HDL-bound miRs with known effects in the cardiovascular system were analyzed in HDL isolated from 
healthy subjects (HS; n=10), patients with stable coronary artery disease (n=10) and patients with an 
acute coronary syndrome (n=10) by quantitative real-time PCR. In HDL from HS, miR-223 was 
detected at concentrations >10,000 copies/µg HDL, and miR-126 and miR-92a at about 3000 
copies/µg HDL. miR concentrations were higher in HDL compared to LDL. The signatures of miRs 
varied only slightly in HDL derived from patients with coronary disease, which showed a reduction of 
HDL-bound miR-92a.  
We did not observe a significant uptake of HDL-bound miRs into endothelial cells, smooth muscle 
cells or peripheral blood mononuclear cells. However, patient-derived HDL transiently reduced miR 
expression particularly when incubated with smooth muscle and peripheral blood mononuclear cells. 
 
Conclusion 
Circulating miRs are detected in HDL and to a less part also by LDL. However, HDL-bound miRs are 
not efficiently taken up by endothelial cells, smooth muscle cells and peripheral blood mononuclear 
cells, in contrast miRs are transiently reduced in these cells. 
Certainly, the present study does not exclude an uptake of HDL-bound miRs in vivo for instance in 
atherosclerotic lesions or foam cells.  
 
Key words: microRNA, high density lipoprotein, circulation, cardiovascular disease, endothelial cells 
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Introduction 
 
MicroRNAs (miRs) are endogenously expressed small non-coding RNAs that regulate gene expression 
on the posttranscriptional level by degradation or translational repression of target mRNAs. Primary 
microRNA transcripts (pri-miRs) are processed by the endonucleases Drosha and Dicer into precursor 
miRs (pre-miRs) and mature miRs. Incorporated into the RNA-induced silencing complex, miRs bind 
to hundreds of target mRNAs and thereby control gene expression patterns. MiRs exhibit important 
functions in the cardiovascular system1-3. For example, the endothelial enriched miR-126 controls 
vascular integrity4, 5 and provides atheroprotective effects6. In contrast, miR-92 blocks blood vessel 
growth and impairs endothelial cell functions7. The miR-143/145 cluster is highly expressed in 
vascular smooth muscle cells and prevents atherosclerotic lesion formation by influencing vascular 
smooth muscle cell phenotypes8-10. Several inflammation-associated miRs have been described such 
as miR-146 and miR-155, which might influence the pro-inflammatory environment and thereby may 
affect atherosclerotic lesion formation11. MiR-targeted therapeutics might become a highly 
interesting novel approach to treat cardiovascular disease12. 
Although miRs act intracellular, they can be released and detected in circulating blood and might be 
used as disease biomarkers13. MiRs are remarkably stable in plasma indicating that they are 
protected from RNase-dependent degradation. Several studies showed that miRs are protected by 
lipid vesicles or protein conjugates14-16. MiRs are actively secreted in microvesicles17, 18, contained in 
apoptotic bodies6 or bound to proteins like Argonaute216. Interestingly, endothelial cell-derived 
apoptotic bodies were shown to contain high levels of miR-126 and reduce atherosclerosis when 
injected in mice models6. Likewise, microvesicles derived from flow-exposed endothelial cells are 
enriched in atheroprotective miRs and inhibit atherosclerotic lesion formation in ApoE-/- mice19. 
Recent studies additionally suggest that circulating high density lipoprotein (HDL) can bind and 
transport endogenous miRs, particularly miR-223, and delivers those to hepatocytes14. The functional 
properties of miRs that are bound to HDL in the cardiovascular system, however, are unclear. 
Elevated high density lipoprotein (HDL) serum levels are associated with reduced risk for coronary 
artery disease (CAD) and HDL from healthy subjects was shown to have potential atheroprotective 
effects by several mechanisms. However, HDL-raising using the CETP inhibitors torcetrapib or 
dalcetrapib has failed to reduce cardiovascular events in patients with coronary disease so far. That 
may in part be related to different vascular effects of HDL from patients with CAD as compared to 
HDL from healthy subjects20.  
In the present study, we addressed whether circulating HDL and also low density lipoprotein (LDL) 
might contain miRs implicated in cardiovascular disease and may control vascular functions by 
delivering miRs. Second, we analyzed HDL-bound miRs in patients with stable CAD and acute 
coronary syndrome (ACS) as compared to HDL from healthy subjects to determine whether the miRs 
signature of HDL is different in patients with coronary disease. Due to the limited amount of RNA we 
could derive from plasma HDL we focused our analysis on a subset of vascular and inflammation-
associated miRs. More precisely, miR-92a, miR-126, miR-150 and miR-378, which are highly 
expressed in endothelial cells, and regulate angiogenesis 5, 7, 21, the smooth muscle specific miR-145, 
which is the most abundant miR in the vascular wall 22, and miR-30c that is highly expressed in 
cardiac myocytes 23 but also is enriched in endothelial cells. miR-146a and miR-155 are involved in 
the control of inflammation associated processes 24, 25 and miR-223 is liver-specific and was shown to 
be bound to HDL in a previous study 14. Among the miRs tested particularly miR-145 and miR-150 
were shown to be released from cells in microvesicles 19, 26. 
Here we demonstrate that miRs known to be relevant in the cardiovascular system are bound to HDL 
albeit at low copy numbers. In contrast even less miRs are bound to LDL. Transfer of artificially bound 
Caenorhabditis elegans miRs by HDL to endothelial cells was very inefficient. However, addition of 
HDL from healthy subjects to endothelial, smooth muscle or peripheral blood mononuclear cells 
reduced endogenous miR levels. The miR signature in HDL isolated from patients with coronary 
disease was only slightly changed as compared to miRs in HDL derived from healthy subjects. 
However, patient-derived HDL had a profoundly changed biological effect on miR expression in 
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peripheral blood mononuclear cells. Thus, HDL induced down-regulation of miR levels is even 
increased after short time points whereas HDL treatment for longer time point promoted up-
regulation of miR levels.  
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Material and Methods 
 
Patient Population  
Patients with stable coronary artery disease (CAD) or an ACS (STEMI or NSTEMI) and healthy subjects 
(without cardiovascular risk factors) were recruited at the University Hospital of Zurich. The diagnosis 
of stable CAD or an ACS was made according to the guidelines of the American College of 
Cardiology/American Heart Association task force27, 28. Patients with an ACS (STEMI and NSTEMI) 
were recruited if they presented within 12 hours after the onset of symptoms and were in a fasting 
state for at least 12 hours. Further exclusion criteria were accompanying infectious, inflammatory or 
autoimmune disorders, advanced kidney or liver failure, diabetes, neoplastic disorders and a history 
of major surgery or trauma within the previous month. 
 
HDL and LDL isolation 
HDL and LDL were isolated from plasma of patients with stable CAD or ACS, and healthy subjects by 
sequential ultracentrifugation (d = 1.063-1.21 g/ml) using solid potassium bromide (Merck KGaA, 
Germany) as described in detail previously 29-31.  
 
Cell culture 
Human umbilical vein endothelial cells (HUVEC) were purchased from Lonza and cultured in 
endothelial basal medium (EBM; Lonza) supplemented with EGM-SingleQuots (Lonza), and 10% fetal 
calf serum (FCS; Invitrogen) until the third passage as previously described32. 
Human Vascular Smooth Muscle Cells (SMC) were purchased from Lonza and cultured in SmBM basal 
medium (Lonza) supplemented with 5% FBS and SmGM-2 SingleQuots (Lonza). SMC were passaged 
after reaching 80% confluency and used until the third passage.  
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation with 
Biocoll (Biochrom) from buffy coat preparations of healthy human volunteers. Cells were transferred 
in RPMI-1640 medium (Sigma) and directly seeded for incubation with HDL. 
 
HDL- and LDL-miR cell culture delivery experiments  
To analyze the uptake of endogenously HDL- and LDL-bound miRs by HUVEC, SMC and PMNC, cells 
were seeded in 24well plates (150,000 HUVEC or SMC/well and 3,000,000 MNC/well). After 
attachment, HUVEC or SMC were starved in EBM or SMC medium with supplements and 0.5% FCS for 
10 hours. PMNC were directly incubated with HDL without starving in RPMI medium. 50 µg/ml or 1 
mg/ml purified HDL was added to the medium, and RNA was isolated after 1/6/16/24 hours 
incubation at 37°C.  
To investigate the uptake of artificially HDL-bound miRs by HUVEC, a complex of purified HDL and 
Caenorhabditis elegans microRNA-39 (cel-miR-39) was formed. Therefore, 80 µg purified HDL was 
incubated with 2 µM mature cel-miR-39 (RNA oligonucleotide, Sigma-Aldrich), cel-miR-39 mimic (Life 
Technologies) or cel-miR-39 precursor (Ambion) for 1 hour at 37°C and overnight at 4°C, rotating. 
Unbound miRs were removed by dialysis. The dialysate was applied to HUVEC (100,000 cells/well, 
24well plate), and incubated for 24 hours at 37°C before RNA isolation. 
 
RNA Isolation and Quantitative Real-time PCR 
RNA was isolated from 10 µl purified HDL. 10 µl HDL results from approximately 250 µl blood serum 
corresponding to HDL protein concentration of 18-25 µg/µl and resulting in 0.72 – 1 µg HDL/µl 
serum. Furthermore, RNA was isolated from 50 µl purified LDL with LDL protein concentration of 3-7 
µg/µl. Isolation was carried out with the blood derivate–specific TRIzol BD from Sigma as described 
previously13. For RNA isolation from Plasma TRIzol BD was used in combination with the miRNeasy 
Kit. RNA from cells was isolated using the miRNeasy Kit according to the manufactures protocol 
(Qiagen). For normalization of miR expression the sample in TRIzol was supplemented with 5 nmol/l 
C. elegans miR-39 (RNA oligonucleotide, Sigma-Aldrich). 
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1 µl RNA of 20 µl total RNA isolated from 10 µl purified HDL or 50 µl purified LDL respectively or 1 µl 
of 30 µl total RNA from 250 µl EDTA-plasma was reverse transcribed using TaqMan reverse 
Transcription Kit (Life Technologies) according to the manufactures instructions. For detection of miR 
expression in cells, 10 ng total RNA were reverse transcribed as described above. 3 µl of the product 
was used for detection of miRs by quantitative PCR using Taqman microRNA Assays (Life 
Technologies) and Applied Biosystems StepOnePlus machine. RNU6 was used for normalization. For 
quantitative detection of pri- and pre-miRs and mRNA (Dicer, Drosha) 600 ng RNA were reverse 
transcribed in a 40 µl reaction using MuLVRT (Life Technologies). SYBR-green qRT-PCR was 
performed using 6 µl 1:5 diluted cDNA. Human ribosomal P0 was used for normalization. For 
calculation of miR copy numbers a standard curve run for each miR with known picomolar 
concentrations of recombinant miRs (RNA oligonucleotides, Sigma-Aldrich) was performed in 
parallel. To calculate the copy number per cell we assumed a RNA concentration of 20 pg per cell.  
 
Statistical analysis 
Data were analyzed with Graphpad Prism 5 using unpaired student’s t-tests with Welch´s correction 
when comparing two conditions, or one-way ANOVA with Bonferroni correction for multiple 
comparisons. Correlation was analyzed using two-sided Spearman´s method. A significance level of 
p<0.05 was considered significant. Data are presented as mean with error bars depicting the 
standard error of the mean (SEM).  
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Results 
 
Quantification of human HDL and LDL containing microRNAs 
First we determined, whether vascular and inflammation-associated miRNAs are bound to HDL and 
LDL at biological relevant concentrations. HDL and LDL were isolated from healthy subjects (n=10 for 
HDL; n=5 for LDL) and miRs were detected by quantitative real-time PCR using recombinant miRs for 
quantification.  
Consistent with previous findings, miR-223 was highly bound to HDL at concentrations of >10,000 
copies/µg HDL (Fig. 1A). The endothelial-enriched miR-126 was detected in HDL with about 2,800 
copies/µg HDL. Likewise, miR-92a, which is highly expressed in endothelial cells, was detected in HDL 
at a similar concentration (Fig. 1A). miR-150, which is released by monocytes and controls 
endothelial cell migration26, was detected albeit at a lower level.The smooth muscle enriched miR-
145, inflammation associated miRs such as miR-146a and miR-155 and the metabolically controlled 
miR-378 were detected although at levels below 120 copies/µg HDL (Fig. 1A). 
Next we determined the miR concentrations bound to LDL. Similar to HDL, miR-223 is also highest 
abundant in LDL. However, only 1,500 copies/µg LDL compared to <10,000 copies/µg HDL miR-223 
were detected (Fig. 1B). The concentrations of LDL-bound miR-126, miR-145, miR-150, miR-378 and 
miR-30c were extremely low (<10 copies /µg LDL). In contrast the pro-atherosclerotic miR-155 is 
higher abundant in LDL compared to HDL (Fig 1B).  
Further on, we examined to what extend HDL bound miRs contribute to the total pool of circulating 
miRs. Therefore, we measured the miR concentration in the total plasma from the same individuals 
of whom HDL was isolated (Fig. 1C) and calculated the percentage of HDL-associated miRs compared 
to the total plasma concentrations. HDL bound miR-223 contributes to about 8% of the total plasma 
pool (Fig. 1D). About 4-5% of circulating miR-126 and miR-378 were associated to HDL, whereas 1-2% 
miR-92a and miR-150 and below 1% of the other miRs were HDL bound (Fig. 1D). Overall a highly 
significant correlation between the absolute concentration of miRs that are bound to HDL and the 
detected circulating miRs in plasma was found (Fig. 1E). However, some miRs (e.g. miR-223, miR-378, 
miR-146a) varied only in the plasma fraction independently on the concentration in HDL and others 
(miR-155, miR-92a) differ in HDL and are more constant in plasma (Fig. 1E). In patients also a 
significant correlation of HDL-bound miRs and plasma miRs were observed (Suppl. Figure 1). 
However, consistent with the data obtained in healthy controls, miR-223 and miR-378 are relatively 
constantly expressed in HDL but differ in plasma. 
 
HDL- and LDL-miR signatures in patients with coronary disease  
HDL derived from patients with coronary disease shows a significantly impaired vasculoprotective 
function31. Therefore, we examined whether miR signatures might be different in HDL isolated from 
these patients. HDL was isolated from patients with stable CAD (n=10) and patients with an ACS 
(n=10) (for patient characteristics see supplemental table 1). miR levels in HDL isolated from patients 
with stable CAD did not significantly differ from those measured in HDL derived from healthy 
subjects. In contrast, in patients with ACS, the absolute copy numbers of HDL-bound miR-92, miR-
146, and miR-30c were significantly reduced as compared to the miR concentrations measured in 
HDL derived from healthy subjects (Fig. 2A).  
In LDL, no significant differences in miR levels isolated from healthy subjects and patients with CAD 
and ACS could be detected (Suppl. Fig. 2). Only miR-126 is slightly elevated in LDL of patients with 
ACS. 
To determine whether there is a change in the distribution of circulating miRs in patients with 
coronary disease, we additionally measured the miR concentrations in plasma of the same patients 
and calculated the percentage of HDL-bound miRs in total plasma. We observed that the percentage 
of HDL-bound miR-92a was reduced in patients with CAD and ACS. Moreover, the level of HDL-bound 
miR-155 was significantly increased in patients with ACS but generally was very low (< 0.5 %) (Fig. 
2B). All other analyzed HDL-bound miRs showed no significant differences between healthy controls 
and patients with CAD. 
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Transfer of HDL –bound miRs to cultured endothelial cells  
Previous studies suggested that HDL bound miRs can be transferred to SRB1 overexpressing baby 
hamster kidney cells and hepatocytes14. Therefore, we examined whether HDL might also deliver 
miRs to endothelial cells.  
Since HDL might influence the biosynthesis and processing of endogenously expressed miRs in 
endothelial cells, we incorporated an artificial C. elegans miR (cel-miR-39) in HDL in vitro. After 
removal of unbound miRs, we determined the uptake in human umbilical venous endothelial cells 
(HUVEC) (Fig. 3A). We analyzed the uptake of the mature single-stranded cel-miR-39 as well as two 
different double-stranded precursor miRs, cel-miR-39 mimic and cel-miR-39 pre-miR (cel-pre-miR-
39). Only around 5 copies HDL-bound mature cel-miR-39 and cel-miR-39 mimic were taken up per 
cell, whereas free mature miRs, which were not bound to HDL did not enter the cells (Fig. 3B). HDL-
bound cel-miR-39 precursor is taken up by endothelial cells in similar amounts, but in contrast much 
higher levels (approximately 50 copies per cell) of HDL-free cel-pre-miR-39 are incorporated in the 
cells (Fig. 3B).  
Together these data demonstrate that HDL bound synthetic miRs can be transferred to cultured 
endothelial cells, however, only very low copy numbers were detected in the recipient cells.  
 
Effect of HDL on miR expression in different cell types 
Because of the low copy numbers of cel-miR-39 detected in HUVEC in the transfer experiments (Fig. 
3A/B), we further analyzed, whether endogenous HDL-bound miRs can be delivered to endothelial 
(HUVEC), smooth muscle (SMC) and peripheral blood mononuclear cells (PBMC). We incubated 
HUVEC, SMC and PBMC with HDL and measured the expression of those miRs, which were associated 
to HDL at concentrations >2000 copies/µg HDL namely miR-223, miR-92a and miR-126 (Fig 1A). No 
significant miR expression changes could be observed in HUVEC after incubation with HDL for 
different time points (Fig. 3D). However, all three analyzed miRs showed a slightly decreased 
expression in HUVEC after 1 hour incubation with HDL (Fig. 3D). Moreover, miR-223 which is highly 
bound to HDL and very low expressed in cultured endothelial cells (CT=30), but induces angiogenesis 
if overexpressed in cultured endothelial cells (Suppl. Fig. 3), was decreased by HDL treatment for 16 
hours (Fig. 3D). Furthermore, increasing the HDL concentration to 1 mg/ml and extending the 
incubation time to 24 hours did not increase the levels of miR-126, miR-92a and miR-223 in 
endothelial cells (Suppl. Fig. 4). 
In SMCs, miR-92a and miR-126 were slightly reduced after 1 hour and not changed after 6 hours 
incubation with HDL (Fig. 3E). miR-223 is only very low expressed in SMC (CT=28) and expression is 
not significantly changed after HDL treatment (Fig. 3E). Most profound changes were observed in 
HDL-treated PBMC. HDL incubation reduced the levels of miR-126 and miR-223 by about 15%. miR-
92a is only slightly reduced after 1 hour, but also significantly reduced after 6 hours incubation with 
HDL (Fig. 3F).  
In summary, no transfer of natively HDL bound miRs to endothelial, smooth muscle and mononuclear 
cells could be documented. In contrast, HDL from healthy subjects overall tend to reduce the levels 
of the measured miRs in all analyzed cell types.  
 
Effects of HDL from patients with coronary disease on different cell types 
Previous studies demonstrated that the HDL-miR profile is significantly different in patients with 
familial hypercholesterolemia compared to healthy subjects14. However, the impact of coronary 
disease is unknown. Therefore, we studied the effect of HDL derived from patients with coronary 
disease on miR expression in different cell types. Likewise to HDL from healthy subjects, HDL from 
patients has no significant effect on miR expression in endothelial cells (Fig. 4A). However, the slight 
reduction of miR expression after 1 hour incubation with HDL from healthy subjects is abrogated 
when using patient derived HDL (Fig. 4A). In contrast to the marginal reduction of miR-92a and miR-
126 in SMC after treatment with HDL from healthy subjects for 1 hour, HDL from patients with CAD 
or ACS increased the levels of miR-92a and miR-126 in SMC (Fig. 4B). No effect on miR expression 
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was observed in SMC after longer incubation with HDL from healthy subjects or patients with 
coronary disease (Fig. 4B). In PBMCs, miR expression is profoundly decreased after incubation with 
HDL from patients with coronary disease. All three miRs are reduced by more than 60% after 
incubation with HDL from patients with CAD, and more than 50% after treatment with HDL from 
patients with ACS (compared to about 15% reduction with HDL from healthy subjects) for 1 hour (Fig. 
4C). On the contrary 6 hours after incubation of PBMC with HDL from patients with coronary disease 
all analyzed miRs are significantly increased again compared to treatment with HDL from healthy 
subjects (Fig. 4C).  
 
Influence of HDL on miR biogenesis in peripheral blood mononuclear cells 
Because we obtained the most profound effect on miR expression change when incubating PBMC 
with HDL, we further tried to elucidate the mechanism how HDL influences miR levels. Therefore we 
estimated expression levels of primary (pri-) and precursor (pre-) miRs (Fig. 5A) and mRNA levels of 
Drosha and Dicer, the enzymes responsible for miR maturation (Fig. 5B) after treatment with HDL 
from healthy subjects as well as HDL from patients with coronary disease. 
PBMC treatment with HDL has no effect on pri- and pre- miR-92a and miR-223. Only pri-miR-223 
expression is slightly but significantly reduced (14+-3%) after incubation with HDL from patients with 
ACS for 6 hours (Fig. 5A). In contrast pri-, pre- and mature miR-126 levels are comparably affected by 
HDL treatment (Fig. 5A and Fig. 4C). More precise, pri- and pri-126 expression is significantly reduced 
after 1 hour incubation with HDL from healthy subjects and patients and pri- and pre-miR-126 levels 
are increased after 6 hour incubation with patient derived HDL, whereas HDL from healthy subjects 
does not lead to a change in pri- and pre-miR-126 expression after 6 hours treatment (Fig. 5A). 
Besides a slight but significant up regulation of Drosha after 1 hour incubation with HDL from 
patients with CAD (11+-2%), both Drosha and Dicer expression are not changed by HDL treatment 
(Fig. 5B). 
In summary, HDL seems to affect miR-126 transcription whereas the modulation of miR-92a and miR-
223 levels is likely due to effects on miR processing.  
 
  
10 
 
Discussion 
The present study for the first time examines HDL associated vascular and inflammation associated 
miRs in healthy subjects and patients with stable CAD or ACS and elucidates to what extend HDL-
miRs are transferred to endothelial cells. Moreover, we investigated the effects of HDL from healthy 
subjects and patients with coronary disease on miR levels that are relevant in the cardiovascular 
system in endothelial, smooth muscle and peripheral blood mononuclear cells. 
We demonstrate that miR-223, miR-92a, and miR-126 were found at highest concentrations in HDL, 
whereas all other miRs tested were below 500 copy numbers/µg HDL. One has also to take into 
account that one µg HDL consists of a large amount of HDL-bound molecules, including proteins, 
lipids and small molecules. Therefore, we have to consider that likely not all HDL-bound molecules 
are binding miRs. However, our finding that miR-223 was the most abundant miR (about 10,000 
copies/µg HDL) is consistent with the study of Vickers et al, showing that this miR is strongly enriched 
in purified HDL14. Overall, the concentration of HDL-miRs strongly correlated to the total plasma pool 
of circulating miRs raising the question of whether the presence of miRs in HDL might reflect 
unspecific binding to circulating miRs in the plasma. However, when calculating the percentage of 
HDL-miRs to the total pool of circulating miRs, we observed that some miRs such as miR-126, miR-
378 and miR-223 were more efficiently bound to HDL as compared to other miRs (Fig. 1D) suggesting 
some specificity of the binding. The maximal levels, however, are still below 10 % of the respective 
plasma miR levels demonstrating that the majority of circulating miRs is not associated with HDL.  
Moreover, we analyzed weather miRs are also associated with HDL`s counterpart LDL. LDL was 
shown to contain a different composition of miRs compared to HDL14 and does not have the same 
functions, for instance is not able to activate endothelial nitric oxide synthase33. Similar to HLD, miR-
223 is also the most abundant miR in LDL, but is reduced by 7-fold compared to HDL. Interestingly 
the only miR that is higher bound to LDL compared to HDL is miR-155 (177 copies/µg LDL vs. 44 
copies/µg HDL). miR-155 promotes atherosclerosis and is specifically expressed in atherosclerotic 
plaques and proinflammatory macrophages34. Furthermore, LDL induces miR-155 expression in 
macrophages34 indicating a possible transfer of LDL bound miR-155 to macrophages and 
atherosclerotic plaques respectively.  
Our data further demonstrate that HDL-miRs are not efficiently taken up by endothelial cells. To 
determine the direct transfer of HDL-miRs to endothelial cells, we loaded HDL with recombinant C. 
elegans miRs and incubated these HDL-miR complexes with endothelial cells in vitro. We indeed 
detected the presence of C. elegans miRs in endothelial cells, however, the copy numbers are very 
low (<10 copies per cell). In lymphocytes, endogenous miRs were shown to be expressed at 5,000 – 
33,000 copies per cell35. MiR-126 and miR-92a were found to be expressed in a similar range in our 
study (data not shown) suggesting that the low number of copies that are transferred by HDL are 
unlikely to have a significant biological function. Previous studies demonstrated that HDL delivers 
exogenous or endogenous miRs to SRBI expressing baby hamster kidney cells and hepatocytes, which 
are known to efficiently take up lipoproteins and oligonucleotides36. Endothelial cells were shown to 
express the SRBI receptor37, but appear less sensitive for the up-take of HDL-bound miRs in our 
setting. In contrast, endothelial cells were shown to efficiently take up microvesicle-embedded miRs6, 
19. Of note, we cannot exclude that differences in the HDL-preparations (e.g. Vickers et al. used 
recombinant HDL which was made free of RNA before loading) might have influenced the results. 
However, we controlled the loading of the HDL with C. elegans miRs (1*107-6*109 copies per µg HDL) 
and the incubation of endothelial cells with high concentrations of native HDL (up to 1 mg/ml) also 
did not increase the endogenous miRs in the cultured endothelial cells (Suppl. Fig. 4).  
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In contrast, native HDL tend to reduce the expression of miR-92a, miR-126 and miR-223. The HDL 
induced transient reduction of miRs was also observed in SMC and a continuous decline of miR 
expression in PBMCs. In addition, our data demonstrate that LDL did not increase the expression of 
the endothelial miRs excluding that LDL bound miRs, which are detected at even lower 
concentrations compared to HDL, are efficiently transferred (Suppl. Fig. 5).  
Previous studies demonstrated that familial hypercholesterolemia is associated with a distinct HDL-
miR pattern compared to normal subjects14, however, the impact of cardiovascular disease was not 
explored. Therefore, we analyzed the miR profile of HDL that was purified from patients with stable 
CAD or ACS. Indeed, some miRs were significantly regulated in HDL from patients compared to 
normal subject. HDL-bound miR-92a was most profoundly reduced in CAD and ACS. Moreover, the 
inflammation associated miR-146 and miR-30c, whose function is unknown, were slightly but 
significantly down-regulated in HDL from ACS patients. Since no significant changes of LDL bound 
miRs were observed in patient derived LDL compared to LDL from healthy subjects LDL-miR pattern 
seems not to be regulated in cardiovascular disease. However, when incubating patient-derived HDL 
with endothelial cells, the transient reduction of endothelial miR levels induced by HDL from healthy 
subjects is abrogated. On the contrary, in smooth muscle cells and peripheral blood mononuclear 
cells the transient reduced miR expression caused by HDL from healthy subjects is even further 
intensified with patient derived HDL. Surprisingly, in PBMC a different effect is seen after longer 
incubation with HDL from patients with CAD or ACS. Here, miR-92a, miR-126 and miR-223 levels are 
increased. This increase was significantly different from what had been observed with normal subject 
derived HDL, which reduced these miRs. The different cellular responses to HDL derived from healthy 
controls versus patients are consistent with previous studies that documented a different biological 
activity of patient versus healthy control-derived HDL30.  
The rapid time course of miR expression changes suggest that HDL influences the turn over or 
processing of miRs. We discovered a differential regulated biogenesis of miR-126 compared to miR-
92a and miR-223 in PBMC. The regulation of miR-126 levels appear to be primarily influence at the 
level of transcription, whereas the reduction of miR-92a and miR-223 is independent on a 
transcriptional change of the pri-miRs or a change in processing into the pre-miR. The reduction may 
be either due to a block of Dicer processing or a destabilization of the mature miR. An interesting 
alternative hypothesis to explain these findings may be that HDL removes miRs from cells. It is well 
known that HDL can be transported through endothelial cells38 and can export lipids from 
atherosclerotic plaques, a process known as reverse cholesterol export39. However, we did not detect 
an increase in miRs in the supernatant of endothelial cells after incubation with HDL.  
Interestingly, the effects on pri- and pre-miR expression after HDL incubation were similar in PBMC 
and endothelial cells (Suppl. Fig. 6). These results indicate a distinct regulation of different miRs by 
HDL. Further on, the different cellular responses to HDL from healthy subjects compared to patients 
derived HDL is also visible at the level of pri- and pre-miRs.  
Together, our data confirm that miRs are transported in plasma by HDL and to a less part also by LDL. 
The contribution of HDL-bound miR to the total miR pool, however, is rather low. The HDL bound 
miRs were not efficiently delivered to endothelial, smooth muscle and peripheral blood mononuclear 
cells suggesting that the HDL associated pool of miRs is not of major importance for the regulation of 
the endothelial functions in these cells. However, the present data do not exclude that HDL-bound 
miRs may be taken up in vivo for instance in atherosclerotic lesions or foam cells.  
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Figure legends 
Figure 1 
HDL, LDL and Plasma miR levels in healthy control subjects. miR expression determined by qPCR 
and copy numbers calculated from a standard curve for each miR with known concentrations. A, 
Detected copy numbers of indicated miRs per µg HDL (n=10). B, Detected copy numbers of indicated 
miRs per µg LDL (n=5) and HDL (n=10). C, Detected copy numbers of indicated miRs per ml plasma 
from the same individuals as HDL was isolated. D, Percentage of HDL bound miRs related to miRs 
detected in total plasma. E, Correlation between HDL bound miRs and plasma containing miRs (two-
sided Spearman correlation). 10µl HDL resulted from 250µl plasma. **p<0.01 HDL versus LDL, 
***p<0.001 HDL versus LDL (t-test with Welch´s correction); n.d.: not detected. 
 
Figure 2 
HDL bound miRs in patients with cardiovascular disease. miR expression determined by qPCR in HDL 
and plasma from control subjects (HS), patients with stable coronary artery disease (CAD) and acute 
coronary syndrome (ACS), n=10 each. Copy numbers calculated from a standard curve for each miR 
with known concentrations. A, Copy numbers of indicated miRs per µg HDL. B, Percentage of HDL 
bound miRs related to miR levels in total plasma. *p<0.05 and **p<0.01 versus HS (Anova with 
Bonferroni´s multiple comparison test). 
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Figure 3 
HDL bound miR delivery to endothelial cells and effect of HDL on different cells. A, Experimental 
setup of HDL cel-miR-39 delivery experiments. HDL from healthy control subjects was incubated as 
indicated with artificial C. elegans miR (cel-miR-39), or two different double-stranded precursor miRs 
(cel-miR-39 mimic and cel-pre-miR-39) respectively, and applied to human umbilical venous 
endothelial cells (HUVEC). After 24 hours RNA was isolated, miRs detected by qPCR, and copy 
numbers calculated from a standard curve with known miR concentrations. B, Detected copy 
numbers per cell above background (HDL alone) in HUVEC incubated with HDL-cel-miR-
39/mimic/precursor complex (HDL+miR), or cel-miR-39/mimic/precursor alone (miR), (n=4). C, 
Experimental setup of endogenously HDL bound miR delivery experiments. HDL from healthy control 
subjects was incubated with HUVEC (D), smooth muscle cells (SMC) (E) or peripheral blood 
mononuclear cells (PBMC) (F) for indicated time points, RNA isolated and miR expression determined 
by qPCR. Relative expression of miR-92a, miR-126 and miR-223 after addition (HDL) or no addition of 
HDL (co) for indicated time points, (n=4-14). Data were normalized to RNU6. *p<0.05 versus co, 
**p<0.01 versus co (t-test with Welch´s correction). 
 
Figure 4 
Influence of HDL from patients with cardiovascular disease on miR expression in different cells. 
Same experimental setup as shown in Figure 3C. Besides HDL from healthy subjects (HS), HDL form 
patients with stable coronary artery disease (CAD) and acute coronary syndrome (ACS) was 
incubated with HUVEC (n=10 each) (A), SMC (n=5 each) (B), and PBMC (n=5 each) (C). Data were 
normalized to RNU6. Relative expression of indicated miRs after addition (HDL) or no addition of HDL 
(-) for denoted time points. *p<0.05 HDL versus -, **p<0.01 HDL versus -, ***p<0.001 HDL versus -, 
#p<0.05 HDL CAD/ACS versus HDL HS ##p<0.01 HDL CAD/ACS versus HDL HS, ###p<0.001 HDL CAD/ACS 
versus HDL HS (Anova with Bonferroni´s multiple comparison test).  
 
Figure 5 
Influence of HDL on miR biogenesis in peripheral blood mononuclear cells  
Same experiment as in Figure 4. A, Relative expression of primary (pri-) and precursor (pre-) miRs. B, 
Relative expression of Drosha and Dicer mRNAs. Data were normalized to ribosomal P0. *p<0.05 HDL 
versus -, **p<0.01 HDL versus -, ***p<0.001 HDL versus -, #p<0.05 HDL CAD/ACS versus HDL HS 
##p<0.01 HDL CAD/ACS versus HDL HS, ###p<0.001 HDL CAD/ACS versus HDL HS (Anova with 
Bonferroni´s multiple comparison test). 
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Response to reviewers 
 
 
Reviewer #1:  
 
MAJOR POINTS: 
 
1) "Incubation of endothelial cells (EC) with native HDL significantly reduced the endogenous 
expression of miR-223, miR-92a and miR-126 suggesting that HDL reduces the biosynthesis or 
enhances the export of miRs from EC.": To get a more insights in these hypotheses, Authors should 
measure primiR and premiR forms of the selected miRs as well as Drosha and Dicer in cultured ECs 
stimulated with endogenous HDL. On the other side, they should incorporate fluorescent miRs in 
cultured ECs and assess if HDL influence the release of these and if so by what mechanisms (for 
example, exosome release by specifically blocking this at some stage). Because Authors noticed that " 
HDL from patients with CAD did not reduce these endothelial miRs but rather induced a significant up-
regulation of endothelial miRs", the aforementioned experiments should be performed using as 
stimulus HDL from either healthy or diseased subjects. 
 
In order to address this question, further experiments with HDL from more healthy subjects were 
performed. The effect of transient miR down regulation is no longer significant, only a trend is 
observable. Nevertheless, primary and precursor miR as well as Drosha and Dicer mRNA levels were 
measured after treatment of endothelial cells with HDL in different concentrations (n=4). No 
significant effects on miR biosynthesis were observed (Suppl. Figure 6, revised manuscript). In 
addition, we analyzed the influence of HDL on miR biogenesis in PBMC in more detail and included 
these data in the revised manuscript (Figures 4 and 5, revised manuscript). The effects in PBMC 
reflect the tendencies observed in endothelial cells  
To analyze the possible release of miRs, we measured miR expression in supernatants of HUVEC after 
incubation with HDL. However, we did not see any increase in miR in the supernatant of cells 
exposed to HDL. These data may suggest that the minor reduction of miRs in the cells is most likely 
due to an enhanced intracellular degradation of mature miRs. 
 
 
2) Authors should study the functional impact of stimulating ECs with HDL-conjugated miRs from 
healthy and disease patients. Here, some in vitro EC biology assay should be performed. 
 
We performed aortic ring and tube formation assays (Figure 1 for the reviewers). In the aortic ring 
assay intensive sprouting was observed after incubation with HDL from healthy subjects whereas 
strongly reduced sprouting was visible after incubation with patient derived HDL (CAD and ACS). In 
addition, a decreased tube formation capacity of endothelial cells was monitored when cells were 
incubated with HDL from patients with coronary disease in contrast to HDL from healthy subjects 
(Figure1 for the reviewers). 
 
 
3) Authors should additional investigate SMCs and monocytes as targets of HDL-miRs. In other words, 
the experiments should not only focus on ECs, but expand to other relevant cell types.  
 
According to the suggestion of the reviewer, we have performed additional extensive studies in SMCs 
and peripheral blood mononuclear cells (PBMC). Interestingly, the effect of HDL on miRs was distinct 
in the different cell types. In SMC, miR-92a and miR-126 were slightly reduced after 1 hour 
incubation with HDL from healthy subjects (Fig. 3E, revised manuscript) and further reduced after 
incubation with patient derived HDL (Fig. 4B, revised manuscript). miR-223 expression is not 
significantly changed after HDL treatment in SMC (Fig. 3E and 4B, revised manuscript). Most 
profound changes were observed in HDL-treated PBMC. Treatment with HDL from healthy subjects 
reduced the levels of miR-126 and miR-223 by about 15%. miR-92a is only slightly reduced after 1 
hour, but also significantly reduced after 6 hours incubation with HDL from healthy volunteers (Fig. 
3F, revised manuscript). In contrast, all three miRs are reduced by more than 60% after incubation 
with HDL from patients with CAD, and more than 50% after treatment with HDL from patients with 
ACS for 1 hour (Fig. 4C, revised manuscript). On the contrary 6 hours after incubation of PBMC with 
HDL from patients with coronary disease all analyzed miRs are significantly increased again compared 
to treatment with HDL from healthy subjects (Fig. 4C).  
These data have been included in the revised manuscript on page x, para y and Figure 3 and 4. 
 
 
MINOR POINTS  
 
1) The title is very broad, but the focus of the paper is not. Title should be more specific and related to 
the experiments developed in the study.  
 
New title? (will have to think about… bin nicht sicher) 
 
 
2) The Authors should describe or speculate if other form of lipoprotein carry miRs and what are the 
processes leading to the appearance of HDL-miR in the circulation. Are cells releasing miRs as already 
conjugated with HDL? Is the encounter happening in the peripheral blood? Please, provide more info 
or speculations.  
 
According to the suggestion of the reviewers, we measured the miR content of other lipoproteins 
such as LDL. Interestingly, we observed a significant change of nearly all miRs when comparing miR 
copies bound to HLD vs. LDL (Fig. 1B, revised manuscript). miR-223 is also highest abundant in LDL, 
but only 1,500 copies/µg LDL compared to <10,000 copies/µg HDL miR-223 were detected. The 
concentrations of most LDL-bound miRs (miR-126, miR-145, miR-150, miR-378 and miR-30c) were 
extremely low (<10 copies /µg LDL). In contrast the pro-atherosclerotic miR-155 is higher abundant in 
LDL compared to HDL. 
No significant differences in miR levels isolated from healthy subjects compared to LDL from patients 
with CAD and ACS could be detected (Suppl. Fig. 2, revised manuscript).Treatment of endothelial 
cells with LDL revealed no influence on endothelial miR expression (Suppl. Fig. 5, revised manuscript).  
These data are included in the revised manuscript on page x, para y and Figure 1 and Suppl. Figures 2 
and 5. 
 
 
3) Correlation of Figure 1D (plasma miRs vs HDL-miRs in healthy subjects) should be repeated in the 
patient populations. Also, Figure 1D. I understand that they wish to demonstrate that miRs that are 
generally at a higher concentration in plasma are also generally at a higher concentration in HDL. But 
it is also clear from the scatterplot that some miRs had an almost constant expression in HDL despite 
a wide range of plasma concentrations, e.g. miR-223, miR-145, miR-378, miR-146a. This is worth 
mentioning.  
 
In Figure 1E we show that HDL-bound miRs significantly correlate with plasma miRs. However, we 
admit that miR-223, miR-146a and miR-378 show a relatively constant expression in HDL and on the 
other hand vary in the plasma of individual subjects. On the other hand miR-155 and miR-92a 
expression differs in HDL and is more constant in plasma.  
Patient populations also show a significant correlation of HDL-bound miRs and plasma miRs (Suppl. 
Figure 1, revised manuscript). However, consistent with the data obtained in healthy controls, miR-
223 and miR-378 are relatively constant expressed in HDL and differ in plasma. According to the 
suggestion of the reviewer, we mentioned this aspect in the revised manuscript (page x, para y) and 
included the correlation analysis in patients as supplementarl Figure 1. 
 
 
4) Details on ethical approval for taking the patient samples (and sending to Frankfurt) are missing  
 
Ulf and Meliana, could you please help to answer this question? 
 
 
5) When describing the different cel-miRs added to HDL, it is worth giving the trademark names for 
the 'mimic' and 'precursor', especially as they give different results later on. How was the 'mature' cel-
miR made/purchased? 
 
According to the suggestion of the reviewer, we added further information in the manuscript as 
follows: 
Ambion Pre-miR Custom Precursor miRNA cel-miR-39 (Life Technologies) 
mirVana miRNA mimic cel-miR-39 (Life Technologies) 
mature cel-miR is an RNA oligonucleotide consisting of the sequence of mature cel-miR-39 according 
to Sanger miRBase (purchased from Sigma Aldrich) 
 
 
6) When giving the HDL protein concentration, is this the concentration in the serum or in the 10ul 
isolated fraction? I would have initially assumed it was the former, and I only ask because I thought 
that normal HDL concentration was much lower than this (0.35 - 1.35 ug/ul)  
 
18-25 µg/µl is the protein concentration in 10 µl HDL concentrate generated from 250 µl serum and 
thus reflects the concentration of 0.72 – 1 µg HDL/µl serum. We added this information to the 
revised manuscript. 
 
 
7) For reverse transcription it is stated that '10ug total RNA' was used. Do they mean 10ng?  
 
We thank the reviewer for noting this mistake. We used 10 ng RNA and accordingly changed the text 
of the revised manuscript. 
 
 
8) Where are the 'recombinant miRs' used for the standard curve from?  
 
The recombinant miRs are RNA oligonucleotides, purchased from Sigma Aldrich. This information 
was added in the revised manuscript. 
 
 
9) There is no mention of a spiked-in exogenous miR when extracting RNA. How was extraction 
efficiency tested? If the extraction efficiency is < 
 
For the experiments shown in Figure 1 and Figure 2 cel-miR-39 was used as a spike in control (RNA 
Oligonucleotide from Sigma-Aldrich). For the calculations of miR copy numbers unnormalized values 
were used. However cel-miR-39 normalized and unnormalization results are comparable. This 
information was added in the revised manuscript. 
 
 
11) Figure 1A and 1B. Need to change y-axis to scientific notation - 1x10n  
 
As recommended by the reviewer, we changed the y-axis. 
 
 
12) Page 8, first line. They mention cel-pre-miR here. Was this a double-strand oligo without a stem-
loop structure or a true premiR?  
 
The precursor miR and the mimic are both double-stand RNA oligonucleotides without a stem-loop 
structure. The difference between both oligos is the stabilizing chemistry (correspondence with Life 
Technologies). 
 
 
13) Can the authors think of a reason why the HDL-free miR 'premiR' and 'mimic' had very different 
levels of incorporation into the endothelial cells?  
 
The reason for the different uptake of precursor and mimic might be due to the different stability 
due to the different chemistry of both oligos.  
 
 
14) Figure 2B, miR92a graph. There is no * above the ACS bar but in the text it says there was a 
significant reduction.  
 
The sentence in the text was changed to make the result more clear.  
 
 
15) Figure 4. For the 1hr HDL bars there is no * above them for miR92a (CAD), miR126 (CAD) and miR-
126 (ACS). Are these definitely not significant differences vs. control?  
 
Shown are the results of ttest with welch´s correction, there is no significance for the mentioned 
groups (CAD miR-92a 1h: p=0.0883; CAD miR-126 1h: p=0.1409; ACS miR-126: 1h p=0.0504). 
 
 
16) The CAD and ACS populations from Fig 4 are also on primary/secondary prevention medications 
(e.g. nearly all on statins vs. none of the healthy subjects). Is there any evidence in the literature that 
these can have an effect on HDL function?  
 
Ulf and Meliana, could you please help to answer this question? 
 
 
17) Supplementary Figure 1: Some error bars are missing in B and D for the control conditions (unless 
all replicates were exactly the same!). Again, check that the differences in panel B vs control aren't 
significant. If there was genuinely hardly any standard error in the control condition replicates, then 
both of these should be significantly different to the pre-223 conditions. Missing scale bars in panels C 
and E  
 
For each experiment in Figure B and D (Suppl. Figure 3, revised manuscript) control was set to 100%, 
therefore there are no error bars for the controls. T-test p-values for Figure 1B are p=0.707 for 1 nM 
precursors and p=0.789 for 10 nM precursors. 
Scale bars were added in C and E. 
 
 
18) There are quite a few minor spelling/formatting errors (e.g. 'ASC' instead of 'ACS', or using 
decimal points instead of a comma for large numbers). 
 
We corrected these errors. 
 
 
 
 
Reviewer #2:  
 
Major comments  
 
1. How many copies of cel-miR-39, cel-miR-39 mimic, and cel-pre-miR-39 were bound to HDL? Was 
there a difference in the binding affinity between the oligonucleotides?  
 
Only a slight difference in binding affinity of the different RNA oligonucleotides was observed (Cel-
miR-39: 5.6 x 109 copies/µg HDL, cel-miR-39 mimic: 1.2 x 107 copies/µg HDL, cel-pre-miR-39: 2.8 x 108 
copies/µg HDL). These data are discussed in the discussion section of the revised manuscript. 
 
 
2. Were the copy numbers of non-HDL bound miRNAs controlled for the amount of HDL bound oligos 
added to HUVECs?  
 
We admit that this was not controlled.  
 
 
3. Previous studies have demonstrated that miRNAs miR-92a, miR-126, and miR-155 are decreased in 
the plasma of CAD patients. Interestingly, HDL bound miR-126 and miR-155 levels were not different 
or rather increased in patient samples in this study. What were the total plasma levels of these 
miRNAs?  
 
As shown in Figure 2 for the reviewer, miR-126 and miR-155 are both reduced in plasma of CAD and 
ACS patients These data suggest that the reduction of miR-126 and miR-155 in total plasma is not 
related to difference in HDL binding activity. 
 
 
4. In the Supplemental Table 1 depicting study population characteristics, surprisingly, CRP levels 
seem to be significantly higher in healthy subjects compared to ACS patients. Could this be due to a 
selection bias? If so, this could have influenced the data regarding inflammation-associated miRNAs 
as well. Please comment.  
 
We thank the reviewer for raising this point. There was a mistake in the statistical analysis. After 
rechecking there is no significant change in CRP levels (one-way Anova). 
 
 
5. In the same Supplement Table 1, p-values indicate that there is a significant difference in HbA1c 
values, but the HbA1c numbers do not reflect any difference. On other hand, in Supplement Table 2, 
there appears to be some difference in HbA1c levels between the 3 gp, but no significance is reported.  
 
There was a mistake in the statistical analysis. After rechecking there is no significant change in 
HbA1c numbers in supplement Table 1 (one-way Anova). The differences in HbA1c levels in Suppl. 
Table 2 are not significant (p-value 0.0692, one-way Anova). 
 
 
6. In the Supplementary figure 1, were sprout formations significantly increased with miR-223 up-
regulation?  
Results are not significant, T-test p-values are p=0.707 for 1 nM precursors and p=0.789 for 10 nM 
precursors. 
 
 
7. The data shown in the Supplement are not sufficient to conclude that miR-223 is an angiogenic 
regulator in endothelial cells. Is miR-223 down regulated in the endothelium of CAD patients? Did 
miR-223 inhibition have any effect on endothelial cell angiogenesis?  
 
Unfortunately, it is not possible to isolate the endothelium of patients to check miR-223 expression. 
We have to admit that miR-223 is only very low expressed in cultured endothelial cells therefore an 
effect on angiogenesis could only be discovered by overexpressing this miR. Therefore, the 
angiogenic activity of endogenous miR-223 is unclear. Accordingly, we modified the result section 
(page x, para y).  
 
 
 
Minor comments  
 
1. Page 9, 'Figure 4C' should be 'Figure 1C'.  
2. Please check the manuscript for typos. 
 
We corrected these errors.  
 
 
Reviewer #3:  
 
Described effects are rather minor and in the present form the manuscript does not provide their 
mechanistic explanation.  
 
Major points:  
 
1. What is the mechanisms of transient down regulation of endothelial microRNAs by HDL-bound 
microRNAS? And, oppositely, the mechanisms responsible for the transient increase in microRNAs 
when ECs were incubated with HDLs from CAD patients? This has not been addressed.  
 
In order to address this question, further experiments with HDL from more healthy subjects and 
patients with coronary disease were performed. However, the effect of transient miR down 
regulation by HDL from healthy subjects is no longer significant, only a trend is observable. The same 
applied also for the increase of miR levels by patient derived HDL. Nevertheless, primary and 
precursor miRs as well as Drosha and Dicer mRNA levels were estimated after treatment of 
endothelial cells with HDL in different concentrations (n=4). No significant effects on miR 
biosynthesis could be observed (Suppl. Figure 6, revised manuscript). However, we analyzed the 
influence of HDL on miR biogenesis in PBMC in more detail and included these data in the revised 
manuscript (Figure 4 and 5, revised manuscript). The effects in PBMC reflect the tendencies observed 
in endothelial cells. 
 
 
2. Did those changes translate to the regulation of the expression of mRNA targets of those 
transferred microRNAs?  
 
To address the question of the reviewer, we elucidated the effect of HDL on miR targets. However, 
consistent with the minor and transient down-regulation of miR levels, miR targets were not 
regulated even when increasing the concentration of HDL to 1 mg/ml (Figure 3 for the reviewer). 
 
 
3. The authors tested, using spheroid and Matrigel assay, the pro-angiogenic effect of miR-223 shown 
in Suppl Fig 1). However, as this miRNAs is the most abundant in HDLs, the effect of HDLs from 
healthy specimens and patients on such processes should be also investigated. 
 
We performed aortic ring and tube formation assays (Figure 1 for the reviewers). In the aortic ring 
assay intensive sprouting was observed after incubation with HDL from healthy subjects whereas 
strongly reduced sprouting was visible after incubation with patient derived HDL (CAD and ACS). A 
decreased tube formation capacity of endothelial cells was monitored when cells were incubated 
with HDL from patients with coronary disease in contrast to HDL from healthy subjects. 
However, we believe that these angiogenesis-regulating effects of HDL are independent on the 
regulation of miR-223 since no up-take was observed in endothelial cells under any conditions. 
 
 
Other comments  
 
1. The sentence on HDL isolation has to be corrected (the words „sequential ultracentrifugation" have 
been used twice)  
 
2. The way of writing numbers and following SI units/other units is not correct. There should be a 
space between the number and unit (eg. should be "20 pg" not "20pg")  
 
These mistakes have been corrected. 
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SUPPLEMENTAL MATERIAL 
 
Supplemental Methods 
 
Spheroid Assay 
Cell spheroids of HUVEC were generated as described previously 1, 2. In vitro angiogenesis was 
quantified by measuring the cumulative length of all sprouts of each spheroid using a digital imaging 
software (AxioVision Rel. 4.8, Carl Zeiss). 10-12 spheroids per group and experiment were analyzed. 
 
Vascular Network Formation 
48 hours after transfection 75,000 HUVEC per well were cultured in 12 well plate coated with 200µl 
Matrigel Matrix Basement Membrane Matrix (BD Biosciences). Tube length was quantified after 24 
hours by measuring the cumulative tube length in three random microscopic fields using a digital 
imaging software (AxioVision Rel. 4.8, Carl Zeiss).  
 
Primer Sequences for qRT-PCR 
The following Primer sequences were used: P0for 5´-TCGACAATGGCAGCATCTAC-3´; P0rev 5´- 
ATCCGTCTCCACAGACAAGG-3´; pri-miR-17-92for 5´-CCAATAATTCAAGCCAAGCAA-3´; pri-miR-17-
92rev: 5´-AAATAGCAGGCCACCATCAG-3´; pre-miR-92for 5´-TCTACACAGGTTGGGATCGG-3 ; pre-miR-
92rev 5´-CGGGACAAGTGCAATACCATA-3´; pri-miR-126for 5´-GCCTCATATCAGCCAAGAAGG-3´; pre-
miR-126for 5´-TGGCGACGGGACATTATTAC-3´; pri/pre miR-126rev 5´-GGACGGCGCATTATTACTCA-3´; 
pri-miR-223for 5´-GGGTGTGACTTCATCATTCC-3´; pre-miR-223for 5´-CCTCCTGCAGTGCCACGC-3´; 
pri/pre miR-223rev 5´-GCATGTGCCGCACTTGGGGT-3´. For detection of Dicer and Drosha mRNA 
QuantiTect Primer Assays (Qiagen) were used. 
 
 
Supplemental Table 1  
Characteristics of the study population in Figure 2 (HDL). 
Characteristics 
Stable coronary 
artery disease 
Acute coronary 
syndrome P-value Healthy Subjects 
  n = 10 n = 10 n = 10   
Demographics 
Age, mean (years) 54 57 54 n.s 
Sex (male/female) 6/4 6/4 6/4 
BP systolic, mean (mm Hg) 
BP diastolic, mean (mm Hg) 
MAP, mean (mm Hg) 98.1 ± 1.9 98.9 ± 4.7 98.2 ± 4 n.s 
BMI, mean (kg/m2) 25 ± 0.6 26 ± 0.9 25 ± 0.4 n.s 
Laboratory parameters         
Glucose (mmol/l) 4.9 ± 0.1 5.7 ± 0.2 5.3 ± 0.3 <0.05 
HbA1c (in %) 5.4 ± 0.05 5.5 ± 0.17 5.4 ± 0.07 n.s 
Total cholesterol (mmol/l)  4.9 ± 0.3 4.3 ± 0.4 4.5 ± 0.2 n.s 
HDL cholesterol (mmol/l) 1.6 ± 0.2 1.3 ± 0.1 1.2 ± 0.1 n.s 
LDL cholesterol (mmol/l) 2.7 ± 0.3 2.7 ± 0.3 2.9 ± 0.2 n.s 
Triglyceride (mmol/l) 1.0 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 n.s 
CRP (µmol/l) 2.0 ± 0.7 1.9 ± 0.6 1.7 ± 0.3 n.s 
Creatinine (μmol/l) 85 ± 2 83 ± 5 83 ± 4 n.s 
Medications 
Statins (in %) 0 70 40 
  
Abbreviations: BP, blood pressure; BMI, body mass index; MAP, mean arterial pressure; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; CRP, C-reactive protein; ACE-I, angiotensin-converting enzyme inhibitor; 
ARB, angiotensin receptor blocker. 
Reported P values are from one-way ANOVA. 
        
Supplemental Table 2  
Characteristics of the study population in Figure 4 (SMC/PBMC) and Suppl. Figure 1 (LDL) 
Characteristics 
Stable coronary artery  Acute coronary  
P-value Healthy Subjects disease syndrome 
  n = 5 n = 5 n = 5   
Demographics 
Age, mean (years) 58 63 52 n.s 
Sex (male/female) 3/2 4/1 3/2 
BP systolic, mean (mm Hg) 116 ± 6  131 ± 14 130 ± 20 n.s 
BP diastolic, mean (mm Hg)  71 ± 9   77 ± 9 81 ± 10 n.s 
MAP, mean (mm Hg) 86  ± 7 95 ± 10  97 ± 13 n.s 
BMI, mean (kg/m2)  22 ± 3  26 ± 3 25 ± 4 n.s 
Laboratory parameters         
Glucose (mmol/l) 4.8 ± 0.4 5.4 ± 0.5 6.7 ± 0.8 <0.01 
HbA1c (in %) 5.6 ± 0.1 5.7 ± 0.6 5.9 ± 0.3 n.s 
Total cholesterol (mmol/l)  5.4 ± 0.3 4.4 ± 1 5.4 ± 0.3 n.s 
HDL cholesterol (mmol/l) 1.8 ± 0.4 1.5 ± 0.5 1.2 ± 0.3 n.s 
LDL cholesterol (mmol/l) 2.9 ± 0.2 2.4 ± 0.6 3.7 ± 0.9 <0.05 
Triglyceride (mmol/l) 0.7 ± 0.1 1.2 ± 0.8 1.0 ± 0.4 <0.05 
CRP (µmol/l) 
Creatinine (μmol/l) 80 ± 3 79 ± 4 66 ± 9 <0.01 
Medications 
Statins (in %) 0 80 0 
Beta blocker (in %) 0 80 0 
Diuretics (in %) 0 60 0 
ACE-I/ARB (in %) 0 0 0 
Calcium blocker 0 40 0 
Aspirin (in %) 0 80 0 
Clopidogrel (in %) 0 80 0   
  
Abbreviations: BP, blood pressure; BMI, body mass index; MAP, mean arterial pressure; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; CRP, C-reactive protein; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker. 
Reported P values are from one-way ANOVA. 
Supplemental Table 3  
Characteristics of the study population in Figure 4 (HUVEC). 
Characteristics 
Stable coronary artery  Acute coronary  
P-value Healthy Subjects disease syndrome 
  n = 10 n = 10 n = 10   
Demographics 
Age, mean (years) 60 60 58 n.s 
Sex (male/female) 6/4 7/4 6/4 
BP systolic, mean (mm Hg) 118 ± 10 127 ± 13 127 ± 21 n.s 
BP diastolic, mean (mm Hg) 74 ± 9 80 ± 8 77 ± 13 n.s 
MAP, mean (mm Hg) 88 ± 8 96 ± 8 94 ± 15 n.s 
BMI, mean (kg/m2) 22 ± 3 28 ± 3 27 ± 5 <0.01 
Laboratory parameters         
Glucose (mmol/l) 4.8 ± 0.7 5.4 ± 0.4 6.8 ± 1.1 <0.001 
HbA1c (in %) 5.5 ± 0.3 5.5 ± 0.6 6.0 ± 0.3 n.s 
Total cholesterol (mmol/l)  5.4 ± 0.6 4.3 ± 0.9 4.9 ± 1.1 <0.05 
HDL cholesterol (mmol/l) 1.8 ± 0.4 1.3 ± 0.4 1.3 ± 0.3 <0.01 
LDL cholesterol (mmol/l) 3.2 ± 0.5 2.4 ± 0.7 3.0 ± 1.1 n.s 
Triglyceride (mmol/l) 0.9 ± 0.3 1.3 ± 0.6 1.4 ± 0.7 n.s 
CRP (µmol/l) 0.8 ± 0.3 4.2 ± 6 4.0 ± 3.6 n.s 
Creatinine (μmol/l) 79 ± 8 88 ± 17 67 ± 11 <0.01 
Medications 
Statins (in %) 0 90 40 
Beta blocker (in %) 0 80 20 
Diuretics (in %) 0 30 10 
ACE-I/ARB (in %) 0 50 50 
Calcium blocker 0 20 10 
Aspirin (in %) 0 90 30 
Clopidogrel (in %) 0 60 30   
  
Abbreviations: BP, blood pressure; BMI, body mass index; MAP, mean arterial pressure; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; CRP, C-reactive protein; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker. 
Reported P values are from one-way ANOVA. 
Supplemental Figure 1 
Supplemental Figure 1 
HDL and Plasma miR levels in patients with cardiovascular disease. Correlation between 
HDL bound miRs and plasma containing miRs  in patients with CAD and ACS (two-sided 
Spearman correlation). 10µl HDL resulted from 250µl plasma.  
1.0×10 02 1.0×10 03 1.0×10 04 1.0×10 05 1.0×10 06 1.0×10 07
1.0×10 05
1.0×10 06
1.0×10 07
1.0×10 08
1.0×10 09
miR-126
miR-92a
miR-223
miR-150
miR-146a
miR-378
miR-145
miR-155
miR-30c
r=0.6982
p=<0.0001
(Spearman, two-sided)
copies miR / 10µl HDL
c
o
p
ie
s
 m
iR
 /
 2
5
0
µ
l 
P
la
s
m
a
1.0×10 01 1.0×10 02 1.0×10 03 1.0×10 04 1.0×10 05 1.0×10 06 1.0×10 07
1.0×10 04
1.0×10 05
1.0×10 06
1.0×10 07
1.0×10 08
1.0×10 09
miR-126
miR-92a
miR-223
miR-150
miR-146a
miR-378
miR-145
miR-155
miR-30c
r=0.7365
p=<0.0001
(Spearman, two-sided)
copies miR / 10µl HDL
c
o
p
ie
s
 m
iR
 /
 2
5
0
µ
l 
P
la
s
m
a
HDL CAD 
HDL ACS 
Supplemental Figure 2 
Supplemental Figure 2 
LDL bound miRs in patients with cardiovascular disease. miR expression determined by 
qPCR in LDL from control subjects (HS), patients with stable coronary artery disease (CAD) 
and acute coronary syndrome (ACS), n=5 each. Copy numbers of indicated miRs per µg 
LDL calculated from a standard curve for each miR with known concentrations.   
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Supplemental Figure 3 
Effect of miR-223 overexpression on angiogenesis in endothelial cells. A, HUVEC were transfected 
with miR-223 precursor (pre-223) or precursor control (pre-co) in indicated concentrations. Data 
were normalized to RNU6. n=4. B, Sprout formation in Spheroid assay (n=10-12 
spheroids/experiment, n=3 experiments. C, Representative images of Spheroids (10mM precursors). 
D, Vascular network formation of HUVEC matrigel (n=6 experiments). *p<0.05 versus co (t-test).  E, 
Representative images of vascular networks (10mM precursors). 
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Supplemental Figure 4 
HDL bound miR delivery to endothelial cells.  
Relative expression of miR-92a, miR-126 and miR-223 after addition of 1 mg/ml  HDL (HDL) or no 
addition of HDL (co) for 1 or 24 hours, (n=5-10). Data were normalized to RNU6.  
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Supplemental Figure 5 
LDL bound miR delivery to endothelial cells.  
Relative expression of miR-92a, miR-126 and miR-223 after addition of 50 µg/ml  LDL (LDL) or no 
addition of LDL (co) for 1 or 24 hours, (n=5-10). Data were normalized to RNU6.  
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Supplemental Figure 6 
Influence of HDL on miR biogenesis in endothelial cells  
Relative expression of primary (pri-), precursor (pre-), mature miRs and Drosha and Dicer mRNAs 
after addition of 50/100/1000 µg/ml  HDL or no addition of HDL (-) for 1 hour. Data were normalized 
to ribosomal P0 or RNU6. *p<0.05 (student´s  ttest) 
* 
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